First Financial Bank Trust Division Lowers Holdings in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

First Financial Bank Trust Division reduced its stake in Johnson & Johnson (NYSE:JNJ) by 4.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,103 shares of the company’s stock after selling 4,533 shares during the period. Johnson & Johnson makes up 1.6% of First Financial Bank Trust Division’s portfolio, making the stock its 16th biggest position. First Financial Bank Trust Division’s holdings in Johnson & Johnson were worth $14,644,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of JNJ. First National Bank of Mount Dora Trust Investment Services raised its position in shares of Johnson & Johnson by 7.2% in the 1st quarter. First National Bank of Mount Dora Trust Investment Services now owns 41,003 shares of the company’s stock worth $6,739,000 after purchasing an additional 2,756 shares during the last quarter. Fulton Bank N.A. increased its stake in Johnson & Johnson by 4.8% during the 1st quarter. Fulton Bank N.A. now owns 53,307 shares of the company’s stock valued at $8,761,000 after purchasing an additional 2,446 shares in the last quarter. Private Asset Management Inc. raised its holdings in Johnson & Johnson by 3.6% in the first quarter. Private Asset Management Inc. now owns 96,388 shares of the company’s stock worth $15,842,000 after buying an additional 3,310 shares during the last quarter. Rempart Asset Management Inc. lifted its stake in shares of Johnson & Johnson by 2.2% in the first quarter. Rempart Asset Management Inc. now owns 127,088 shares of the company’s stock worth $20,887,000 after buying an additional 2,735 shares in the last quarter. Finally, Thomasville National Bank grew its holdings in shares of Johnson & Johnson by 7.5% during the first quarter. Thomasville National Bank now owns 24,128 shares of the company’s stock valued at $3,164,000 after buying an additional 1,677 shares during the last quarter. Hedge funds and other institutional investors own 67.25% of the company’s stock.

JNJ has been the topic of several recent analyst reports. Credit Suisse Group increased their target price on Johnson & Johnson from $168.00 to $193.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. Raymond James lifted their price objective on Johnson & Johnson from $158.00 to $183.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $157.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, January 27th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $178.00 to $187.00 and gave the company an “overweight” rating in a report on Wednesday, January 27th. Finally, Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $178.60.

NYSE JNJ traded up $0.24 on Thursday, hitting $163.85. 30,726 shares of the company traded hands, compared to its average volume of 8,177,090. The business’s 50 day moving average price is $161.06 and its 200-day moving average price is $154.38. Johnson & Johnson has a 52-week low of $133.65 and a 52-week high of $173.65. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $431.37 billion, a price-to-earnings ratio of 25.76, a P/E/G ratio of 3.06 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Monday, January 25th. The company reported $1.86 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.82 by $0.04. The firm had revenue of $22.50 million for the quarter, compared to analysts’ expectations of $21.62 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.88 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading: What causes a recession?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.